Sunlindac

Product manufactured by Direct Rx

Application Nr Approved Date Route Status External Links
ANDA072051 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Carefully Consider The Potential Benefits And Risks Of Sulindac Tablets And Other Treatment Options Before Deciding To Use Sulindac Tablets. Use The Lowest Effective Dose For The Shortest Duration Consistent With Individual Patient Treatment Goals (See Warnings). Sulindac Tablets Are Indicated For Acute Or Long-Term Use In The Relief Of Signs And Symptoms Of The Following: Osteoarthritis Rheumatoid Arthritis1 Ankylosing Spondylitis Acute Painful Shoulder (Acute Subacromial Bursitis/supraspinatus Tendinitis) Acute Gouty Arthritis 1 The Safety And Effectiveness Of Sulindac Tablets Have Not Been Established In Rheumatoid Arthritis Patients Who Are Designated In The American Rheumatism Association Classification As Functional Class Iv (Incapacitated, Largely Or Wholly Bedridden, Or Confined To Wheelchair; Little Or No Self-Care).

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Sulindac SULINDAC ZINC4475353

Comments